Advertisement

Clinical Rheumatology

, Volume 31, Issue 11, pp 1549–1557 | Cite as

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis

  • Cheng-Tao Yang
  • Chang-Fu Kuo
  • Shue-Fen Luo
  • Kuang-Hui Yu
Original Article

Abstract

The aim of this retrospective study was to examine the predictors of discontinuation of anti-tumor necrosis factor (TNF) therapy due to adverse events in Chinese patients with rheumatoid arthritis (RA). Anti-TNF-related adverse events were recorded and analyzed in 217 consecutive patients with RA followed in our institution from 2003 to 2010. Time to discontinuation of anti-TNF-α therapy was estimated using survival analysis techniques. The anti-TNF agents administered were etanercept in 181 patients and adalimumab in 36 patients. The mean age at diagnosis was 45.2 ± 13.5 years, and mean age at initiation of anti-TNF therapy was 51.8 ± 13.0 years. The mean duration of anti-TNF agent use was 36.0 ± 26.5 months (range, 1.4–87.0; median, 26.4 months). Of the 217 patients, 39 (18.0 %) developed adverse events [etanercept in 34 (18.8 %] and adalimumab in 5 (13.9 %)] during the treatment period (tuberculosis in 5, bacterial infections in 19, virus infection in 7, neuropathy in 3, malignancy in 3, other drug-related events in 1, and appendicitis in 1). In patients with RA, older age (≥55 years) at initiation of anti-TNF therapy [odds ratio (OR), 3.20; 95 % confidence interval (CI), 1.67–6.20; p < 0.001], Cr ≥1.5 mg/dL (OR, 5.72; 95 % CI, 1.17–27.90; p = 0.031), and occurrence of adverse events (OR, 3.82; 95 % CI, 1.75–8.35; p = 0.001) were associated with increased likelihood of discontinuation of anti-TNF treatment. In the present study, a significant proportion (7.8 %, 17/217) of patients with RA discontinued anti-TNF treatment because of adverse events. In the elderly and in patients with renal insufficiency, caution is needed when starting anti-TNF treatment.

Keywords

Adverse event Infection Rheumatoid arthritis Tumor necrosis factor 

Notes

Disclosures

None.

References

  1. 1.
    McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219PubMedCrossRefGoogle Scholar
  2. 2.
    Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108PubMedCrossRefGoogle Scholar
  3. 3.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376PubMedCrossRefGoogle Scholar
  4. 4.
    Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846PubMedCrossRefGoogle Scholar
  5. 5.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int 28:261–269PubMedCrossRefGoogle Scholar
  6. 6.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. Scand J Rheumatol 37:6–12PubMedCrossRefGoogle Scholar
  7. 7.
    Konttinen L, Honkanen V, Uotila T, Pöllänen J, Waahtera M, Romu M et al (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916–922PubMedCrossRefGoogle Scholar
  8. 8.
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939PubMedCrossRefGoogle Scholar
  9. 9.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  10. 10.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45PubMedCrossRefGoogle Scholar
  11. 11.
    Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW et al (2009) Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 108:310–319PubMedCrossRefGoogle Scholar
  12. 12.
    Chou CT (2006) The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 16:206–213PubMedCrossRefGoogle Scholar
  13. 13.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  14. 14.
    Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286–1291PubMedCrossRefGoogle Scholar
  15. 15.
    Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59:800–806PubMedCrossRefGoogle Scholar
  16. 16.
    Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY et al (2010) Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong—the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 28:679–685PubMedGoogle Scholar
  17. 17.
    Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9:52PubMedCrossRefGoogle Scholar
  18. 18.
    Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM et al (2009) The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36:2171–2177PubMedCrossRefGoogle Scholar
  19. 19.
    Dahl SL, Samuelson CO, Williams HJ, Ward JR, Karg M (1990) Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 10:79–84PubMedGoogle Scholar
  20. 20.
    Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL et al (2009) Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68:1470–1473PubMedCrossRefGoogle Scholar
  21. 21.
    van Schaardenburg D, Breedveld FC (1994) Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 23:367–378PubMedCrossRefGoogle Scholar
  22. 22.
    Yung RL (2000) Changes in immune function with age. Rheum Dis Clin North Am 26:455–473PubMedCrossRefGoogle Scholar
  23. 23.
    Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transpl Int 22:1041–1050PubMedCrossRefGoogle Scholar
  24. 24.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMedCrossRefGoogle Scholar
  25. 25.
    Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884–1894PubMedCrossRefGoogle Scholar
  26. 26.
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155PubMedCrossRefGoogle Scholar
  27. 27.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737–744PubMedCrossRefGoogle Scholar
  28. 28.
    Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847–861PubMedCrossRefGoogle Scholar
  29. 29.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J et al (2011) Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 38:1273–1281PubMedCrossRefGoogle Scholar
  30. 30.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560–568PubMedCrossRefGoogle Scholar
  31. 31.
    Levalampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int 28:261–269PubMedCrossRefGoogle Scholar
  32. 32.
    Patkar NM, Teng GG, Curtis JR, Saag KG (2008) Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 20:320–326PubMedCrossRefGoogle Scholar
  33. 33.
    Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT (2006) Mycobacterium tuberculosis in Taiwan. J Infect 52:77–85PubMedCrossRefGoogle Scholar
  34. 34.
    Ornstein MH, Sperber K (1996) The anti-inflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum 39:157–161PubMedCrossRefGoogle Scholar
  35. 35.
    Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, British Society for Rheumatology Biologics Register (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56:2896–2904PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Cheng-Tao Yang
    • 1
  • Chang-Fu Kuo
    • 2
  • Shue-Fen Luo
    • 2
  • Kuang-Hui Yu
    • 2
    • 3
  1. 1.Division of Chinese MedicineChang Gung Memorial Hospital and Chang Gung UniversityTao-YuanTaiwan
  2. 2.Division of Rheumatology, Allergy and ImmunologyChang Gung Memorial Hospital and Chang Gung UniversityTao-YuanTaiwan
  3. 3.Division of Allergy, Immunology and RheumatologyChang Gung Memorial HospitalTao-Yuan CountyTaiwan

Personalised recommendations